EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Facilitating Next‐Generation Pre‐Exposure Prophylaxis Clinical Trials Using HIV Recent Infection Assays: A Consensus Statement from the Forum HIV Prevention Trial Design Project

Neil Parkin, Fei Gao, Eduard Grebe, Amy Cutrell, Moupali Das, Deborah Donnell, Ann Duerr, David V Glidden, James P Hughes, Jeffrey Murray, Michael N Robertson, Joerg Zinserling und 3 weitere

Clinical Pharmacology & Therapeutics · 2023-07 · 114 (1) · 29-40

DOI: 10.1002/cpt.2830 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical Pharmacology & Therapeutics, online erschienen am 05.01.2023. Verfasst von Neil Parkin und 14 weiteren Autor:innen. Beteiligte Einrichtung: Data First Consulting, Sebastopol, California, USA. Hauptthemen laut MEDLINE: Pre-Exposure Prophylaxis, Anti-HIV Agents, HIV Infections. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 87 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Bill and Melinda Gates Foundation, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Standard‐of‐care HIV pre‐exposure prophylaxis (PrEP) is highly efficacious, but uptake of and persistence on a daily oral pill is low in many settings. Evaluation of alternate PrEP products will require innovation to avoid the unpractically large sample sizes in noninferiority trials. We propose estimating HIV incidence in people not on PrEP as an external counterfactual to which on‐PrEP incidence in trial subjects can be compared. HIV recent infection testing algorithms (RITAs), such as the limiting antigen avidity assay plus viral load used on specimens from untreated HIV positive people identified during screening, is one possible approach. Its feasibility is partly dependent on the sample size needed to ensure adequate power, which is impacted by RITA performance, the number of recent infections identified, the expected efficacy of the intervention, and other factors. Screening sample sizes to support detection of an 80% reduction in incidence for 3 key populations are more modest, and comparable to the number of participants in recent phase III PrEP trials. Sample sizes would be significantly larger in populations with lower incidence, where the false recency rate is higher or if PrEP efficacy is expected to be lower. Our proposed counterfactual approach appears to be feasible, offers high statistical power, and is nearly contemporaneous with the on‐PrEP population. It will be important to monitor the performance of this approach during new product development for HIV prevention. If successful, it could be a model for preventive HIV vaccines and prevention of other infectious diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pre-Exposure ProphylaxisAnti-HIV AgentsHIV InfectionsHumansResearch DesignSample Size

Substanzen

Anti-HIV Agents

Autor:innen und Institutionen

  • Data First Consulting, Sebastopol, California, USA.
  • Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
  • Vitalant Research Institute, San Francisco, California, USA.
  • Edward Grebe Consulting, Cape Town, South Africa.
  • ViiV Healthcare, Research Triangle Park, North Carolina, USA.
  • Gilead Sciences, Foster City, California, USA.

ORCID-Profile: Veronica Miller

Förderung

  • Bill and Melinda Gates Foundation
  • National Institutes of Health

Zitieren

APA

Parkin, N., Gao, F., Grebe, E., Cutrell, A., Das, M., Donnell, D., Duerr, A., Glidden, D. V., Hughes, J. P., Murray, J., Robertson, M. N., Zinserling, J., Lau, J., Miller, V., & Forum for Collaborative Research Recency Assay Working Group (2023). Facilitating Next‐Generation Pre‐Exposure Prophylaxis Clinical Trials Using HIV Recent Infection Assays: A Consensus Statement from the Forum HIV Prevention Trial Design Project. Clinical Pharmacology & Therapeutics, 114(1), 29-40. https://doi.org/10.1002/cpt.2830

Vancouver

Parkin N, Gao F, Grebe E, Cutrell A, Das M, Donnell D, et al. Facilitating Next‐Generation Pre‐Exposure Prophylaxis Clinical Trials Using HIV Recent Infection Assays: A Consensus Statement from the Forum HIV Prevention Trial Design Project. Clinical Pharmacology & Therapeutics. 2023;114(1):29-40. doi:10.1002/cpt.2830

BibTeX
@article{Parkin2023,
  author = {Parkin, Neil and Gao, Fei and Grebe, Eduard and Cutrell, Amy and Das, Moupali and Donnell, Deborah and Duerr, Ann and Glidden, David V and Hughes, James P and Murray, Jeffrey and Robertson, Michael N and Zinserling, Joerg and Lau, Joseph and Miller, Veronica and Forum for Collaborative Research Recency Assay Working Group, Forum for Collaborative Research Recency Assay Working Group},
  title = {Facilitating Next‐Generation Pre‐Exposure Prophylaxis Clinical Trials Using HIV Recent Infection Assays: A Consensus Statement from the Forum HIV Prevention Trial Design Project},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2023},
  volume = {114},
  number = {1},
  pages = {29--40},
  doi = {10.1002/cpt.2830}
}
Kostenlos starten →